【热门产品推介】Research Grade Anti-RSV pre-F/pre-Fusion glycoprotein F0
RSV基因组大小约15~16 kb，编码11种蛋白，包括8种结构蛋白和3种非结构蛋白(NS1、NS2和M2-2)，结构蛋白包括3种跨膜表面蛋白(G、F、SH)、2种基质蛋白(M和M2-1)、3种核壳蛋白(L、N和P)。
货号：DVV02822
产品链接：http://www.antibodysystem.com/product/9575.html
物种反应性：Human respiratory syncytial virus A (strain A2)
形式：Liquid
存储缓冲区：0.01M PBS, pH 7.4.
浓度：1 mg/ml
纯度：>95% by SDS-PAGE.
克隆性：Monoclonal
应用：Research Grade Biosimilar
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
参考文献：
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. PMID: 36535957
Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein. PMID: 30769923
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. PMID: 27682426
Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring. PMID: 32197348
Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates. PMID: 32045432
The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein. PMID: 31288455
The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. PMID: 28604155
Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. PMID: 31623333
呼吸道合胞病毒(respiratory syncytial virus，RSV)感染是一个全球性的健康问题，目前临床上仍缺乏特异的治疗手段。接种疫苗主动免疫预防或使用抗体制剂被动免疫预防是避免重症感染和减少死亡的重要措施。针对不同的人群，须研制不同类型的RSV疫苗：减毒活疫苗对婴儿来说，可能是最佳选择；亚单位疫苗有引起增强型呼吸道疾病的风险，不适合RSV血清学阴性的婴幼儿接种，主要适用于老年人和孕妇。研发安全且有效的RSV疫苗难度大，虽然已有30余种RSV疫苗进入临床研究阶段，并显示出应用潜力，其中F纳米颗粒疫苗已率先进入Ⅲ期临床试验，但在老年人和孕妇中未达预期效果。在RSV流行季节前，使用特异性抗体制剂也是预防高危人群严重RSV感染性疾病的有效手段。长效单克隆抗体MEDI8897比帕利珠单抗更具成本效益，已进入Ⅲ期临床试验，且获得优先研发资格。多克隆免疫球蛋白RI-002已在免疫缺陷人群中显示出较好的预防效果，具有进一步研发的现实意义。
